Kornimate/medical-research-clean huggingface dataset:
role of bronchoscopy in assessment of patients with post-intubation tracheal stenosis

Conditions: Tracheal Stenosis

Summary: 1. to estimate the importance of bronchoscopic treatment of tracheal stenosis and its effectiveness and safety. 2. to diagnose and evaluate tracheal stenosis characteristics as location, vertical extension and severity of obstruction.

post intubation tracheal stenosis (pi) was recognized in 1880, after prolonged endotracheal intubation in 4 patients with upper airway obstruction.the most common causes of acquired tracheal stenosis are endotracheal intubation and tracheostomy. tracheal stenosis is a surgical problem managed non operatively by bronchoscopic dilation, endoluminal treatment with lasers, and stenting. bronchoscopic management have a good success rate. pi and post tracheostomy stenosis (pt) are recognized with an 4.9 cases per million per year in the general population. prolonged intubation can result in tracheal stenosis at various levels within the trachea.tracheal stenosis occurs at the endotracheal tube cuff site in one third of the reported pi cases \[9\] and appears as a web-like fibrous. the mainly postulated cause is loss of regional blood flow.this injury begins within the first hours of intubation, and healing of the damaged areas within 3 to 6 weeks. large volume, low pressure cuffs has reduced the occurrence of cuff injury.patients in the icu are common to have respiratory involvement, with 30-50% of the admissions requiring the use of mechanical ventilation.flexible bronchoscopy has become the procedure of choice in most examinations of the tracheobronchial tree.the incidence of pi tracheal stenosis ranges from 6-21% and following tracheostomy ranges from 0.6-21%.

Eligibility criteria:
inclusion criteria: 1. meticulous history and clinical examination 2. chest x-ray (cxr) 3. spirometry 4. flexible bronchoscopy 5. rigid bronchoscopy (when needed). exclusion criteria: 1. patient refusal. 2. any coagulation disorder. 3. untreatable life-threatening arrhythmias. 4. allergy to anaesthesia. 5. poor general condition.
norepinephrine or phenylephrine in bolus for hypotension in cesarean delivery

Conditions: Hypotension; Spinal Anesthesia

Summary: this study evaluate the ability of phenylephrine and of noradrenaline to maintain normal systemic arterial blood pressure and heart rate in healthy pregnant women submitted to cesarean section with spinal anesthesia. half of participants will receive bolus of phenylephrine while the other half will receive bolus of noradrenaline.

this is a prospective, randomized, double-blind, comparative two-group clinical study to observe two vasopressor drugs, phenylephrine and noradrenaline, in the ability to maintain systemic arterial pressure in pregnant women after spinal anesthesia for cesarean section; based on the hypothesis that, since noradrenaline has a predominant alpha-adrenergic action and a weak 1- beta-adrenergic beta action, it could be as capable of maintaining blood pressure effectively as phenylephrine, but with a lower frequency of bradycardia; patients who meet the inclusion criteria will be randomly assigned to one of the groups to be studied: group f - phenylephrine at a dose of 100mcg bolus and n - noradrenaline at the dose of 5mcg. one of these drugs will be used whenever systolic blood pressure drops below 10% of the baseline, additional doses will be allowed whenever necessary, aiming at maintaining the systolic blood pressure at baseline values; the blood pressure will be measured non-invasively and the heart rate by pulse oximeter and electrocardiogram.

Eligibility criteria:
inclusion criteria: * pregnant women, with single gestation, with cesarean programming to be performed under spinal anesthesia; * age above 18 years; * physical state american society of anesthesiologists (asa) ii and iii; * weight between 50kg and 120kg; * height between 140cm and 180cm. exclusion criteria: * refusal to participate in the study; * pregnant women with fetus with known abnormalities; * pregnant women with cardiovascular disease; * pregnant women with pregnancy-specific hypertensive disease; * allergy to any medication to be used in the study; * users of monoamine oxidase inhibitors; * users of tricyclic antidepressants; * emergency caesarean section due to acute fetal distress; * situations in which the sensory level after single intrathecal injection of the local anesthetic does not reach at least t6 within 5 minutes after spinal anesthesia.

Keywords: phenylephrine norepinephrine cesarean delivery under spinal anesthesia
volumetric analysis of bone following jaw cysts enucleation with and without alb-prf

Conditions: Jaw Cysts

Summary: cyst is the main cause for longstanding swelling in the mandible or the maxilla, its enlargement usually results in resorption and weakening of bone. thus the treatment of the cysts is essential to preserve the bone and the adjacent vital structures. healing of the bone defect and its surrounding soft tissues is a critical issue that needs concerns. although the platelet rich fibrin has promising effects in wound healing, it can resorb during 10-14 days. thus a new autologous platelet concentrate is introduced by kawasi et al that can remain stable for 4-6 months called albumin prf.


Eligibility criteria:
inclusion criteria: * patients suffering from jaw cystic cavity volume greater than 1cm3 * patients with no gender predilection that agreed to present for follow-up visits for a minimum postoperative period of 6 months. * cystic lesion that requires removal under local or general anaesthesia. exclusion criteria: * medically compromised patients contradicting operation. * patients with history of chemotherapy or radiotherapy. * patients with low level of platelet count. * patients with anticoagulant therapy. * patients who are unable to attend follow up appointments
patient control epidural versus conventional epidural.

Conditions: Post Operative Pain, Acute; Sedation Score; Degree of Motor Block; Length of Hospital Stay; Amount of Analgesic Used

Summary: as one of the complications of thr is post operative pain, which usually requires epidural catheter insertion. we are comparing the effect of patient control epidural versus conventional epidural for patient's satisfaction.

more than 20 years of successful usage of epidural analgesia for post operative pain treatment include intermittent provider-administer bolus, patient control analgesia and continuous epidural infusion with or without patient control epidural analgesia. the main drawback of conventional epidural infusion is that it does not allow for individual variation in management of pain. as a result, patient control epidural analgesia has replaced it in recent years.3. it has been demonstrated that continuous epidural infusion with patient control epidural analgesia is highly effective at providing consistent analgesia, improving patient satisfaction, and reducing the workload of anesthesia provider but it is linked to higher local anesthetic consumption4 in patient undergoing thr, patient control epidural analgesia may be considered as an appropriate alternative for managing post operative pain.

Eligibility criteria:
inclusion criteria: age \>18 years. asa 1-2 on pre anesthesia evaluation. spontaneous breathing. spo2 \>95% informed consent for participation. exclusion criteria: a history of long-term opioid therapy (use of opioid analgesic at doses higher than codeine 120mg/day, hydrocodone 40mg/day, tramadol 200mg/day or oxycodone 40mg/day 0-4 days before surgery). indication of revision surgery during immediate post operative care. acute skin disease. patients' refusal. asa 3 and 4. hypersensitivity to study drugs.

Keywords: patient control epidural analgesia conventional epidural
french therapeutic education program aiming to improve laryngectomized patients' and their family caregiver's quality of life

Conditions: Patients With Total Laryngectomy and Their Close Relatives

Summary: the therapeutic education of patients and their close relations is, as yet, poorly developed in france in the field of oncology (pérol2007), in particular for cancers of the upper aerodigestive tract (allison2010). in the case of pharyngeal and laryngeal cancer, total laryngectomy associated with radiotherapy remains a reference treatment for advanced stage cancers. this mutilating surgical procedure has a major impact on the patient's life, due to its physical and functional sequelae: phonatory (loss of physiological voice), feeding, olfactory and aesthetic (tracheostomy). its psychosocial consequences are also important, owing to the biographical disruption and the identity-related metamorphoses associated with illness and its treatment, which alter the quality of life not only of patients, but also of their close relations. indeed, transformation is not only at individual level, it also impacts the life of close relations, in particular spouses, who share the day-to-day lives of patients (babin 2010). currently, care for laryngectomized patients consist essentially in informing and educating them on certain technical procedures (cannula replacement, mucosity aspiration, tracheostomy or phonatory implant cleaning) during hospital admission. such education may be formalized and dispensed within the context of a therapeutic education program. the issue of this study will be to determine what therapeutic education program we should offer patients and their close relations in order to accompany them throughout their experience of laryngectomy and to reduce its impact on social and professional aspects of life.


Eligibility criteria:
patient inclusion criteria * patients over 18 having been treated by total laryngectomy for cancer of the larynx, pharynx or cervical esophagus. * patients accepting to participate in the study (informed consent form explained and signed). * patient having not been undergone a pte * person affiliated with an appropriate social security system. close relation inclusion criteria * person over 18 designated as being a close relation by the laryngectomized patient (confidential person, spouse, parent, natural support person or any person whose quality of life may be impacted by the patient's laryngectomy). * close relation accepting to participate in the study (informed consent form explained and signed). * person authorized by the patient to be contacted by the investigator, in order to propose his/her participation in the research study. * person affiliated with an appropriate social security system. patient exclusion criteria - physical, psychical, psychiatric or cognitive incapacity to answer to questions or participate in interviews/sessions. close relation exclusion criteria - physical, psychical, psychiatric or cognitive incapacity to answer to questions or participate in interviews/sessions.
assessment of a diagnostic medical device for the inr (international normalized ratio) measurement

Conditions: Healthy; Heart Valves; Arrhythmias, Cardiac; Thromboembolism

Summary: the purpose of this study is to assess the measurement conformity of an in vitro diagnostic device measuring the inr (international harmonized ratio).

the investigators will assess the performance of an in vitro diagnostic device for assessing the inr. the evaluation will consist of make several inr measurements using the device and compare these measures to the reference value. the inr will be measured using the study device on capillary blood drops taken from the fingertip. in the same way a venous blood sampling will be carried out to measure a reference inr. a total of 20 healthy subjects and 180 patients treated with vitamin k agonist will be enrolled in the study.

Eligibility criteria:
inclusion criteria: * patients treated with vitamin k agonist or healthy volunteers * for healthy volunteers : body mass index between 18 ans 29 kg/m² * no acute disease in the previous month exclusion criteria: * pregnant woman

Keywords: inr coagulation vitamin k antagonist
contrast specific echocardiogram versus left ventricular opacification (lvo) imaging settings

Conditions: Contrast Echocardiography Imaging

Summary: this study compares "contrast specific imaging setting" images with "left ventricular opacification (lvo)" images taken on the same group of patients at different points in time, to see if one is more effective at assessing the function of the heart.

ultrasound testing of the heart using a "dye" or contrast is often used to get clear pictures of the heart in many heart conditions. when this test is done when the heart is working hard, such as when exercising, this is called contrast stress echocardiography. current guidelines recommend the method called "contrast specific imaging setting," as the best way of looking at the main pumping part of the heart. however, it is not known if it provides better pictures when compared to a different method called "left ventricular opacification (lvo)." this study will compare pictures in patients who have had tests done using both ways of looking at the heart and will compare; lvo; enhanced and unenhanced lvebd; lvo imaging with contrast specific imaging wall motion classification and lvo to contrast specific imaging left ventricular ejection fraction (lvef). the comparison will be done by a group of experts in cardiac ultrasound.

Eligibility criteria:
inclusion criteria: 1. participants enrolled in the luminity 422 study that also have complete data with contrast specific imaging obtained within a 60 day window. 2. participants who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained. exclusion criteria: 1. unwilling / unable to give informed consent

Keywords: coronary artery disease myocardial contrast echocardiography left ventricle opacification
fmrf combined with 30% ssa in the treatment of rosacea

Conditions: Rosacea

Summary: this study was a single-center, case-by-case, bilateral facial comparison study. a total of 15 patients were included. on the day of enrollment, after the completion of the test items, treatment was carried out (full face gold micro-needling + 30% salicylic acid on the half face), and on-site follow-up was conducted 1 week later, 2 weeks later follow-up was conducted and the second acid brushing treatment was performed, 4 weeks later follow-up was conducted and the third acid brushing treatment was performed, on-site follow-up was conducted at the 8th week and the 12th week, and the follow-up contents included: visia photography, camera photography, non-invasive skin testing, questionnaire assessment, etc. the study duration was 12 weeks.

this study is a single-center case-control study with half-side face as the control group. according to the inclusion and exclusion criteria, 15 patients with rosacea (erythema and telangiectasia type) were included. before and after treatment, various skin indicators of the patients were evaluated and followed up. through screening, subjects who met all the inclusion criteria and did not violate any of the exclusion criteria would be included in this study. the researchers measured and evaluated the various skin indicators of the patients. on the day of enrollment, the project was completed and treatment was carried out (full face gold micro-needling + 30% salicylic acid on half-side face), and then on-site follow-up was conducted 1 week later, 2 weeks later, 4 weeks later, 8 weeks later, and 12 weeks later. the follow-up contents included: visia photography, camera photography, non-invasive skin detection, questionnaire assessment, etc. the study duration was 12 weeks.

Eligibility criteria:
inclusion criteria: 1. according to the latest diagnostic criteria of the american rosacea society (2017 version) - annex 1, patients diagnosed with the main phenotype of erythema and telangiectasia. 2. the therapeutic response to the medication is unsatisfactory and the condition is prone to relapse. 3. age range: 18 to 60 years old 4. the patient voluntarily participated in this clinical study and signed the written informed consent form. exclusion criteria: 1. the patient has other skin disorders on the face, such as melasma, freckles and seborrheic dermatitis, which may affect the judgment of the test results. 2. individuals who are allergic to the test drug or have hypersensitive constitution. 3. patients who are pregnant, about to become pregnant or are lactating. 4. patients with acne during the consultation. 5. patients who had undergone facial injections or surgeries within the past two months before the trial. 6. patients with immunodeficiency diseases and abnormal coagulation function.

Keywords: rosacea
evaluation of the evoke radiofrequency device for improvement of skin appearance

Conditions: Skin Laxity

Summary: evaluation of the evoke radiofrequency device for improvement of skin appearance

the aim of the study is to evaluate the safety, efficacy, patient comfort, and patient satisfaction after evoke treatment

Eligibility criteria:
inclusion criteria: * - signed informed consent to participate in the study. * female and male subjects, 35 and 75 years of age at the time of enrolment * if female, not pregnant, lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrolment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence). * in addition, negative urine pregnancy test as tested before each treatment and at the last visit for women with childbearing potential (e.g. not menopause). * general good health confirmed by medical history and skin examination of the treated area. * willing to have photographs and images taken of the treated areas to be used de-identified in evaluations, publications and presentations. * the patients should be willing to comply with the study procedure and schedule, including the follow up visit, and will refrain from using any other aesthetic treatment methods for the last 6 months and during the entire study period. exclusion criteria: * - pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body. * permanent implant in the treated area such as metal plates and screws, silicone implants or an injected chemical substance, unless deep enough in the periostal plane. * current or history of skin cancer, or current condition of any other type of cancer, or premalignant moles. * severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled hypertension, and liver or kidney diseases. * pregnancy and nursing. * impaired immune system due to immunosuppressive diseases such as aids and hiv, or use of immunosuppressive medications. * patients with history of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area, may be treated only following a prophylactic regimen. * poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction. * any active condition in the treatment area, such as sores, psoriasis, eczema, and rash. * history of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin. * history of bleeding coagulopathies or use of anticoagulants in the last 10 days. * any surgery in treated area within 3 months prior to treatment. * six months delay is required if other recent treatments like light, co2 laser or rf were performed on the same area. * use of isotretinoin (accutane®) within 6 months prior to treatment. * as per the practitioner's discretion, refrain from treating any condition that might make it unsafe for the patient
long-term vesicular monoamine transporter ii imaging and clinical assessment of parkinson's disease progression

Conditions: Parkinson Disease

Summary: a total 40 pd subjects will be included in this study. pd subjects between 20 and 80 years of age may be eligible for this study. candidates are screened with a medical history and physical examination, and blood test.

the primary objective of this protocol is to assess the rate of change in striatal 18f-dtbz uptake in a cohort of parkinson's disease patients. this study is expected to be completed in a period of 4 years.

Eligibility criteria:
inclusion criteria: 1. male or female age 20 years to 80 years. 2. patients should be fulfilled criteria of diagnosis of parkinson disease of "possible" or "probable" pd1. 3. patients who provide a written informed consent prior to study entry. if the patient is incapable of informed consent, the caregiver may consent on behalf of the patient (the patient must still confirm assent) exclusion criteria: 1. significant recent (within 6 months) history of neurological (including stroke and brain trauma) or psychiatric disorder. 2. alcohol or substance abuse. 3. history or presence of qtc prolongation. (\>500msec) 4. history of intracranial operation, including thalamotomy, pallidotomy, and/or deep brain stimulation. 5. unable to stay still in the mri or pet scanner for 30 minutes. 6. pregnancy and breast feeding. 7. hepatic dysfunction with liver function test (alanine aminotransferase \[alt\] and aspartate aminotransferase \[ast\]) of \> 3x the upper limit of normal

Keywords: 18f-dtbz av-133 imaging
eye drops study for myopia control in schoolchildren

Conditions: Myopia, Progressive; Atropine Allergy

Summary: the myopia prevalence in schoolchildren is high in taiwan. the myopia progression is fast in children and often associated high myopia in later life. this prospective and randomized study to investigate the effect of myopia control in myopic children with ultra low concentrations of atropine eye drops and/or low concentrations of anti-allergic and inflammatory eye drops.

myopia onset earlier in children who would suffer a high degree of myopia in the future adulthood.and higher risk for retinal detachment, macular degeneration, and even blindness. in taiwan, myopia macular degeneration is the first place of irreversible blind cause in the elderly. the evidence based medicine shows atropine is the most effective treatment for the progression of myopia so far, but the side effects including photophobia and near blurred vision often disturbing patients and resulting poor compliance and high drop-out rate. recently, the studies from taiwan and singapore showed that low concentrations of atropine (0.05% or 0.01%) can effectively inhibit the myopia progression, reduce the symptoms of photophobia, and to achieve favorable myopia control. previous study found that myopia and allergic conjunctivitis and inflammation were related. the investigators designed a prospective and randomized study to investigate the effect of myopia control in myopic children with ultra low concentrations of atropine eye drops and/or low concentrations of anti-allergic and inflammatory eye drops. due to environmental factors such as near work, after school class and outdoor activity are also great associated with myopia, the questionnaires also are collected in this study.

Eligibility criteria:
inclusion criteria: * myopia diagnosed with the spherical equivalent refraction at least -0.5 diopter (d) * must be able to use eye drops exclusion criteria: * astigmatism -1.50 d or greater * strabismus * amblyopia * cataract * glaucoma * any ocular diseases ocular surgery * history of systemic diseases (ex. asthma, heart disease...) * contact lenses user * orthokeratology user

Keywords: myopia schoolchildren atropine allergy eye drops outdoor near work